{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:09:40Z","timestamp":1793686180044,"version":"4.5.1"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis & Rheumatology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"Objective<\/jats:title>The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis (RA<\/jats:styled-content>). Patients with RA<\/jats:styled-content> have elevated interleukin\u20106 (IL<\/jats:styled-content>\u20106) levels; however, the utility of IL<\/jats:styled-content>\u20106 as a predictor of treatment response is unclear. This study was undertaken to investigate, by post hoc analysis, whether baseline IL<\/jats:styled-content>\u20106 levels are predictive of sarilumab treatment responses in 2 phase III<\/jats:styled-content> studies.<\/jats:p><\/jats:sec>Methods<\/jats:title>Serum IL<\/jats:styled-content>\u20106 concentrations were measured in patients with RA<\/jats:styled-content> prior to receiving sarilumab 200 mg (n = 148) or adalimumab 40 mg (n = 152) every 2 weeks (in the MONARCH<\/jats:styled-content> trial; ClinicalTrials.gov identifier: NCT<\/jats:styled-content>02332590) or sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks plus methotrexate (MTX<\/jats:styled-content>) (n = 401, n = 396, and n = 397, respectively) (in the MOBILITY<\/jats:styled-content> trial; ClinicalTrials.gov identifier: NCT<\/jats:styled-content>01061736). Efficacy and patient\u2010reported outcomes were compared between and within groups according to IL<\/jats:styled-content>\u20106 tertile using linear and logistic regression.<\/jats:p><\/jats:sec>Results<\/jats:title>In MONARCH<\/jats:styled-content>, patients with high baseline IL<\/jats:styled-content>\u20106 levels (all \u22653 times the upper limit of normal; n = 100) had higher disease activity at baseline than those with low IL<\/jats:styled-content>\u20106 levels (n = 100). The magnitude of clinical improvement over 24 weeks with sarilumab versus adalimumab was greater in patients with high compared to those with low baseline IL<\/jats:styled-content>\u20106 levels. In MOBILITY<\/jats:styled-content>, compared to patients with low IL<\/jats:styled-content>\u20106 levels (n = 397), patients with high IL<\/jats:styled-content>\u20106 levels (n = 398) had higher disease activity and joint damage at baseline, were more likely to have joint progression, and had less clinical improvement over 52 weeks\u2019 treatment with placebo plus MTX<\/jats:styled-content> compared to sarilumab 150 mg or 200 mg plus MTX<\/jats:styled-content>. Baseline IL<\/jats:styled-content>\u20106 and C\u2010reactive protein levels were both predictive of outcomes. Safety profiles were similar between defined IL<\/jats:styled-content>\u20106 tertiles.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>IL<\/jats:styled-content>\u20106 may be a prognostic marker of disease progression and severity, and patients with high IL<\/jats:styled-content>\u20106 levels may be likely to benefit from sarilumab compared to adalimumab or MTX<\/jats:styled-content>. Prospective validation is warranted to confirm the results of these post hoc analyses.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.41299","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T14:03:30Z","timestamp":1588082610000},"page":"1456-1466","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Association of High Serum Interleukin\u20106 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis"],"prefix":"10.1002","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-2722","authenticated-orcid":false,"given":"Anita","family":"Boyapati","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Msihid","sequence":"additional","affiliation":[{"name":"Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[{"name":"Cardiff University School of Medicine Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center Palo Alto California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Lam","sequence":"additional","affiliation":[{"name":"Atrium Health Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sadeh","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinreich","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"e_1_2_7_4_1","first-page":"141","article-title":"Predictors of response to biologic therapies in rheumatoid arthritis","volume":"7","author":"Chaparro LM","year":"2011","journal-title":"Reumatol Clin"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17720366"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes078"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1366-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39714"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00185"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep35242"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09629359890875"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes113"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep329"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003199"},{"key":"e_1_2_7_15_1","unstructured":"Actemra (tocilizumab) prescribing information.Genentech; June2019. URL:https:\/\/www.gene.com\/downl\u200boad\/pdf\/actem\u200bra_presc\u200bribing.pdf."},{"key":"e_1_2_7_16_1","unstructured":"Kevzara (sarilumab) prescribing information.Regeneron Sanofi Genzyme; April2018. URL:http:\/\/produ\u200bcts.sanofi.us\/kevza\u200bra\/kevza\u200bra.pdf."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39093"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1132-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02163-6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.1998.141"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1614-z"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1096-9"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.12.1298"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000287"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2309-0"},{"issue":"10","key":"e_1_2_7_31_1","article-title":"Higher levels of interleukin\u20106 as well as soluble interleukin\u20106 receptor leads to worse clinical and radiographic prognosis in rheumatoid arthritis patients treated with tocilizumab [abstract]","volume":"69","author":"Nishina N","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.022"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132055"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165799"}],"container-title":["Arthritis & Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:03:32Z","timestamp":1759925012000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/art.41299"],"URL":"https:\/\/doi.org\/10.1002\/art.41299","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"assertion":[{"value":"2019-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}